Recherche Recherche de structure
wx_img
Inquiry Form
  1. Home
  2. Fezolinetant

Fezolinetant

Dec 10, 2023, VEOZA (fezolinetant) approved by European Commission for treatment of vasomotor symptoms associated with menopause.
VEOZAH is the first and only neurokinin 3 (NK3) receptor antagonist that blocks NKB from binding on KNDy neurons to help reduce heat signals that trigger VMS. First-in-class fezolinetant brings women a new nonhormonal therapy for hot flashes.
In May 2023, FDA has approved VEOZA(fezolinetant) 45 mg once daily for the treatment of moderate to severe VMS due to menopause.

(R)-4-(2,4-dimethoxybenzyl)-3-methylpiperazin-2-one
(R)-4-(2,4-dimethoxybenzyl)-3-methylpiperazin-2-one
CM131538
1383146-20-0
(6R)-1-[(2,4-dimethoxyphenyl)methyl]-5-ethoxy-6-methyl-1,2,3,6-tetrahydropyrazine
(6R)-1-[(2,4-dimethoxyphenyl)methyl]-5-ethoxy-6-methyl-1,2,3,6-tetrahydropyrazine
CM1044500
1429560-52-0
3-methyl-1,2,4-thiadiazole-5-carbohydrazide
3-methyl-1,2,4-thiadiazole-5-carbohydrazide
CM392029
1375066-73-1
3-methyl-5-[(8R)-8-methyl-5H,6H,7H,8H-[1,2,4]triazolo[4,3-a]pyrazin-3-yl]-1,2,4-thiadiazole
3-methyl-5-[(8R)-8-methyl-5H,6H,7H,8H-[1,2,4]triazolo[4,3-a]pyrazin-3-yl]-1,2,4-thiadiazole
CM1044501
1429558-08-6
4-Fluorobenzoyl chloride
4-Fluorobenzoyl chloride
CM343690
403-43-0
(R)-3-Methylpiperazin-2-one
(R)-3-Methylpiperazin-2-one
CM120132
922178-61-8
2,4-Dimethoxybenzaldehyde
2,4-Dimethoxybenzaldehyde
CM243667
613-45-6